Eloxx Pharmaceuticals (ELOX) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends Eloxx Pharmaceuticals (NASDAQ:ELOX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage20.20%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$36,000.00Number OfInsiders Selling(Last 3 Years)0 Get ELOX Insider Trade Alerts Want to know when executives and insiders are buying or selling Eloxx Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELOX Insider Buying and Selling by Quarter Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Eloxx Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/29/2021Daniel E GeffkenCFOBuy50,000$0.72$36,000.00 (Data available from 1/1/2013 forward) ELOX Insider Trading Activity - Frequently Asked Questions Who is on Eloxx Pharmaceuticals's Insider Roster? The list of insiders at Eloxx Pharmaceuticals includes Daniel E Geffken. Learn more on insiders at ELOX. What percentage of Eloxx Pharmaceuticals stock is owned by insiders? 20.20% of Eloxx Pharmaceuticals stock is owned by insiders. Learn more on ELOX's insider holdings. Eloxx Pharmaceuticals Key ExecutivesMr. Sumit Aggarwal M.B.A. (Age 51)President, CEO & Director Compensation: $839.67kMr. Daniel E. Geffken M.B.A. (Age 67)Interim CFO, Principal Financial Officer & Principal Accounting Officer Compensation: $63.96kMs. Barbara RyanInvestor Relations OfficerDr. Ali Hariri M.D.Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Pieris Pharmaceuticals Insider Buying Precigen Insider Buying Anavex Life Sciences Insider Buying PTC Therapeutics Insider Buying Amgen Insider Buying Gilead Sciences Insider Buying argenx Insider Buying BioNTech Insider Buying Biogen Insider Buying Moderna Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:ELOX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
